LDK378

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Conditions

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Trial Timeline

Jun 1, 2012 → Jan 1, 2016

NCT ID

NCT01634763

About LDK378

LDK378 is a phase 1 stage product being developed by Novartis for Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK). The current trial status is completed. This product is registered under clinical trial identifier NCT01634763. Target conditions include Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK).

What happened to similar drugs?

8 of 20 similar drugs in Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) were approved

Approved (8) Terminated (4) Active (8)

✅Everolimus (RAD001)NovartisApproved

✅everolimusNovartisApproved

✅Imatinib MesylateNovartisApproved

✅NilotinibNovartisApproved

✅Sacituzumab Govitecan-hiyGilead SciencesApproved

✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved

✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01947608	Pre-clinical	Completed	—	—	Non-small Cell Lung Cancer (NSCLC)
NCT02450903	Phase 2	Completed	Aug 21, 2015	May 24, 2018	Non-Small-Cell Lung Cancer
NCT02040870	Phase 1/2	Completed	Mar 7, 2014	Jul 27, 2017	Non-Small Cell Lung Cancer
NCT01950481	Phase 1	Completed	Jan 1, 2014	Sep 1, 2016	Normal Hepatic Function
NCT01685138	Phase 2	Completed	Dec 20, 2012	Jan 22, 2018	Non-Small Cell Lung Cancer
NCT01685060	Phase 2	Completed	Nov 26, 2012	Mar 29, 2016	Non-Small Cell Lung Cancer
NCT01634763	Phase 1	Completed	Jun 1, 2012	Jan 1, 2016	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
NCT01283516	Phase 1	Completed	Jan 24, 2011	May 3, 2016	Tumors Characterized by Genetic Abnormalities of ALK

Competing Products

20 competing products in Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

See all competitors

Product	Company	Stage	Hype Score
mRNA-4359	Moderna	Phase 2	0
mRNA-4106	Moderna	Phase 1	0
mRNA-4157 + Pembrolizumab + SoC Treatment	Merck	Phase 1	33
E7050	Eisai	Phase 1	29
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)	Syros Pharmaceuticals	Phase 1	11
Cixutumumab	Eli Lilly	Phase 1	29
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
ZN-c3 + Bevacizumab + Pembrolizumab	Zentalis Pharmaceuticals	Phase 1	11
IMC-18F1	Eli Lilly	Phase 1	29
OKI-179	OnKure Therapeutics	Phase 1	19
ACR-2316	Acrivon Therapeutics	Phase 1	26
LY2875358 + Erlotinib + Gefitinib	Eli Lilly	Phase 1	29
Tomivosertib (eFT-508)	eFFECTOR Therapeutics	Phase 2	25
SPYK04	Chugai Pharmaceutical	Phase 1	33
AUBE00 + Cetuximab	Chugai Pharmaceutical	Phase 1	36
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	21
ERY974	Chugai Pharmaceutical	Phase 1	29
DS3610a	Daiichi Sankyo	Phase 1	36
Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oral	Daiichi Sankyo	Phase 1	29